Risk of ipsilateral breast event after surgical excision increases over time
the ONA take:
Women with ductal carcinoma in situ (DCIS) who undergo surgical resection without radiation have an increased risk of developing recurrence of DCIS or invasive disease, and that risk increases over time.
A prospective clinical trial sought to determine the 12-year risk of an ipsilateral breast event (IBE) in women with DCIS of the breast treated with lumpectomy without radiation. The results were presented in part at the San Antonio Breast Cancer Symposium.
Study participants were enrolled into two cohorts, not randomly assigned. Cohort 1 was 561 patients with low- or intermediate grade DCIS, tumor size 2.5 cm or smaller. Cohort 2 was 104 patients with high-grade DCIS, tumor size 1 cm or smaller.
Patients underwent excision of the DCIS tumor with a minimum negative margin width of at least 3 mm, and 30% of the patients received tamoxifen (not randomly assigned). An IBE was defined as local recurrence of DCIS or invasive carcinoma in the treated breast. Patients were followed for a median of 12.3 years. There were 99 IBEs, of which 51 were invasive.
Results show that 12-year rates of developing an IBE was 14.4% for cohort 1 and 24.6% for cohort 2; 12-year rates for developing an invasive IBE were 7.5% in cohort 1 and 13.4% in cohort 2. Study cohort and tumor size were significantly associated with risk for IBE.
Women with ductal carcinoma in situ who undergo surgical resection without radiation have an increased risk of developing recurrence.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|